Health Care & Life Sciences » Biotechnology | Halozyme Therapeutics Inc.

Halozyme Therapeutics Inc. | Income Statement

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Sales/Revenue
54,799.40
75,334.00
135,057.00
146,691.00
316,613.00
151,862
Cost of Goods Sold (COGS) incl. D&A
6,245.80
22,732.00
29,245.00
33,206.00
31,152.00
10,136
Gross Income
48,553.70
52,602.00
105,812.00
113,485.00
285,461.00
141,726
SG&A Expense
128,987.30
114,238.00
133,264.00
196,695.00
204,459.00
255,256
EBIT
80,433.60
61,636.00
27,452.00
83,210.00
81,002.00
113,530
Unusual Expense
-
1,400.00
-
-
-
-
Interest Expense
3,274.10
5,581.00
5,201.00
19,977.00
21,984.00
18,041
Pretax Income
83,478.60
68,375.00
32,231.00
101,861.00
61,610.00
123,993
Income Tax
-
-
-
1,162.00
1,361.00
43,663
Consolidated Net Income
83,478.60
68,375.00
32,231.00
103,023.00
62,971.00
80,330
Net Income
83,478.60
68,375.00
32,231.00
103,023.00
62,971.00
80,330
Net Income After Extraordinaries
83,478.60
68,375.00
32,231.00
103,023.00
62,971.00
80,330
Net Income Available to Common
83,478.60
68,375.00
32,231.00
103,023.00
62,971.00
80,330
EPS (Basic)
0.74
0.56
0.25
0.81
0.45
0.56
Basic Shares Outstanding
112,805.40
122,690.00
126,704.00
127,964.00
136,419.00
143,599
EPS (Diluted)
0.74
0.56
0.25
0.81
0.45
0.56
Diluted Shares Outstanding
112,805.40
122,690.00
126,704.00
127,964.00
139,068.00
143,599
EBITDA
79,206.70
59,874.00
25,775.00
80,800.00
83,163.00
111,142
Non-Operating Interest Income
229.20
242.00
422.00
1,326.00
2,592.00
7,578

About Halozyme Therapeutics

View Profile
Address
11388 Sorrento Valley Road
San Diego California 92121
United States
Employees -
Website http://www.halozyme.com
Updated 07/08/2019
Halozyme Therapeutics, Inc. is a biopharmaceutical company specializes in research, development, and commercialization of human enzymes and other drug candidates. It focuses on novel oncology therapies that target the tumor microenvironment. Its products include PEGPH20, HTI-1511, PEG-ADA2, and HYLENEX recombinant.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.